Get started
Work

Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial

Year: 2026
Type: article
Abstract: Not available.
DOI: 10.3324/haematol.2025.300144
Authors: Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi, Alphan Kupesiz, Maria Gabriela A. Dias Matos, Yogi Chopra, Sunil Bhat, Ho Joon Im, Tayfun Güngör, Meng-Yao Lu, Tommaso Stefanelli, Severine Peyrard, Yvonne Smith, Karen Sinclair, Cristina Diaz-de-Heredia
Institutions: Università Cattolica del Sacro Cuore, Bambino Gesù Children's Hospital, Acıbadem Adana Hospital, Seoul National University, Seoul National University Children's Hospital, Saitama Children's Medical Center, Nagoya University, Akdeniz University, Support group for adolescents and children with cancer, University of Toronto, Hospital for Sick Children, Narayana Health, Mazumdar Shaw Medical Centre, Asan Medical Center, University of Ulsan, University Children's Hospital Zurich, National Taiwan University Hospital, Novartis (Switzerland), Novartis (Ireland), Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,157
Award: G200894337
OpenAlex ID: W7130512215
FWCI: 4.478
Cites:
Cited by: 1
Related to: